We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Growth Seen for European POC Coagulation Testing

By HospiMedica staff writers
Posted on 15 Dec 2003
The point-of-care (POC) testing market in Europe will grow from 140 million euros in 2003 to more than 350 million euros in 2009, according to a new analysis from international consultants Frost & Sullivan (London, UK). More...
This figure includes near-testing and self-testing devices. The growth is being fostered by the clinical results and the lower costs of an increasing number of outpatient anticoagulation clinics.

POC coagulation analyzers are gaining preference in the critical care, surgery, and home testing environments, since they provide rapid and accurate information for improved patient monitoring. Coagulation testing looks at endpoint measurements between bleeding and clotting, and the new technologic developments are expected to allow a comprehensive assessment of the complex interactions between various blood clotting factors.

"The biggest advantage of POC testing is the decrease in turn-around time because most POC analyses are performed on whole blood, minimizing any transport and logistic handovers that normally occur within laboratory testing,” explained Shree Viswadia, a research analyst with Frost & Sullivan.

Market concerns include slow implementation of insurance reimbursement and the development of new thrombin inhibitor drugs that could gradually eliminate the need for routine testing. Nonetheless, POC testing is finding increasing acceptance across Europe, with Germany, Italy, and the United Kingdom having the largest number of users.




Related Links:
Frost & Sullivan >>

Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.